Sirolimus topical - Palvella Therapeutics/TransDerm
Alternative Names: PTX 022; QTORIN™ 3.9% rapamycin; QTORIN™ 3.9% rapamycin anhydrous gel; Rapamycin topical - Palvella Therapeutics/TransDerm; TD201Latest Information Update: 30 Oct 2024
At a glance
- Originator Palvella Therapeutics; TransDerm
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Lymphangioma; Pachyonychia congenita
- Phase II Basal cell nevus syndrome
Most Recent Events
- 22 Oct 2024 Palvella Therapeutics plans the phase II TOIVA trial in Vascular Malformations (In children, In adults, In the elderly, In Adolescents) (Topical, Gel), December 2024 (NCT06653842)
- 01 Jul 2024 Phase-III clinical trials in Lymphangioma in USA (Topical) (NCT06239480)
- 01 Dec 2023 Palvella Therapeutics has patent pending for anhydrous gel formulations of rapamycin in Europe, and Japan